Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO

Dell’Aquila, Emanuela; Rossini, Daniele; Galletti, Alessandro; Stellato, Marco; Boccaccino, Alessandra; Conca, Veronica; Germani, Marco Maria; Bergamo, Francesca; Daniel, Francesca; Spagnoletti, Andrea; Provenzano, Leonardo; Tomasello, Gianluca; Zaniboni, Alberto; Buonadonna, Angela; Fanchini, Laura; Cupini, Samanta; Carlomagno, Chiara; Caponnetto, S; Rapisardi, Stefania; Santini, Daniele

doi:10.1016/j.clcc.2022.02.003

Cited by 6 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another variable that we evaluated was obesity. In a study evaluating the relationship between long-term outcomes of colorectal cancer and BMI, no significant relationship was found between oncologic outcomes and BMI 3 . Since we know that cancer patients can be sarcopenic without being cachectic, we wanted to evaluate the obesity status in our study.…”

Section: Discussionmentioning

confidence: 97%

Predicción de resultados a corto plazo tras hemicolectomía derecha laparoscópica. ¿Es la sarcopenia superior a otros métodos?

Erözkan¹,

Vatansever²,

Tamam³

et al. 2024

CIRU

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Predicción de resultados a corto plazo tras hemicolectomía derecha laparoscópica. ¿Es la sarcopenia superior a otros métodos?

Erözkan¹,

Vatansever²,

Tamam³

et al. 2024

CIRU

View full text Add to dashboard Cite

show abstract

“…There are conflicting studies on the importance of body mass index in the prognosis of advanced CRC 22–24 . In many other solid tumours, however, a favourable effect of a higher BMI on overall survival has been found, which is referred to as the obesity paradox 25 .…”

Section: Discussionmentioning

confidence: 99%

“…There are conflicting studies on the importance of body mass index in the prognosis of advanced CRC. [22][23][24] In many other solid tumours, however, a favourable effect of a higher BMI on overall survival has been found, which is referred to as the obesity paradox. 25 In early stage CRC, the negative correlation between BMI and sarcopenia was found to be an underlying factor of this effect.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Deep learning‐based assessment of body composition and liver tumour burden for survival modelling in advanced colorectal cancer

Keyl

Hosch

Berger

et al. 2022

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Background Personalized therapy planning remains a significant challenge in advanced colorectal cancer care, despite extensive research on prognostic and predictive markers. A strong correlation of sarcopenia or overall body composition and survival has been described. Here, we explore whether automated assessment of body composition and liver metastases from standard of care CT images can add to clinical parameters in personalized survival risk prognostication. Methods We retrospectively analysed clinical imaging data from 85 patients (50.6% female, mean age 58.9 SD 12.2 years) with colorectal cancer and synchronous liver metastases. Pretrained deep learning models were used to assess body composition and liver metastasis geometry from abdominal CT images before the initiation of systemic treatment. Abdominal muscle-to-bone ratio (MBR) was calculated by dividing abdominal muscle volume by abdominal bone volume. MBR was compared with body mass index (BMI), abdominal muscle volume, and abdominal muscle volume divided by height squared. Differences in overall survival based on body composition and liver metastasis parameters were compared using Kaplan-Meier survival curves. Results were correlated with clinical and biomarker data to develop a machine learning model for survival risk prognostication. ResultsThe MBR, unlike abdominal muscle volume or BMI, was significantly associated with overall survival (HR 0.39, 95% CI: 0.19-0.80, P = 0.009). The MBR (P = 0.022), liver metastasis surface area (P = 0.01) and primary tumour sidedness (P = 0.007) were independently associated with overall survival in multivariate analysis. Body composition parameters did not correlate with KRAS mutational status or primary tumour sidedness. A prediction model based on MBR, liver metastasis surface area and primary tumour sidedness achieved a concordance index of 0.69. Conclusions Automated segmentation enables to extract prognostic parameters from routine imaging data for personalized survival modelling in advanced colorectal cancer patients.

show abstract

“…However, in the study by Artaç et al ( 16 ), among patients undergoing treatment with bevacizumab-based regimens, the prognosis may be poorer for obese individuals compared to non-obese patients with mCRC. A pooled analysis revealed that BMI was not a prognostic factor for PFS and OS in mCRC patients treated with triplet therapy in addition to bevacizumab ( 18 ). To date, there remains controversy regarding the association between BMI and the prognosis of mCRR patients receiving bevacizumab, thereby, a meta-analysis is highly warranted.…”

Section: Introductionmentioning

confidence: 99%

Effect of body mass index on survival in patients with metastatic colorectal cancer receiving chemotherapy plus bevacizumab: a systematic review and meta-analysis

Lang,

Tong,

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

AimThis systematic review and meta-analysis was to evaluate the relationship between body mass index (BMI) and the clinical outcomes in patients with metastatic colorectal cancer (mCRC) undergoing treatment with bevacizumab plus chemotherapy.MethodsThe search for relevant literature was conducted across PubMed, Embase, Cochrane Library, and Web of Science, with the final search date being October 4, 2023. We utilized the weighted mean differences (WMDs), risk ratios (RRs), or Hazard ratios (HRs) as the metric for effect sizes, which were accompanied by 95% confidence intervals (CIs).ResultsA total of 9 studies were included for analysis. The results indicated that non-obese patients with mCRC undergoing treatment with bevacizumab experienced a reduced overall survival (OS) at the six-month compared to their obese counterparts (RR: 0.97, 95% CI: 0.94 to 1.00, p = 0.047). Furthermore, no significant differences in one-year, two-year, and five-year OS, as well as PFS and median OS, were observed between obese and non-obese mCRC patients undergoing treatment with bevacizumab plus chemotherapy.ConclusionThese findings suggest that obesity may play a role in the short-term OS of patients with mCRC undergoing bevacizumab treatment. The clinical implications of these findings underscore the importance of considering patients’ BMI in the context of mCRC care. This study may also help guide personalized treatment strategies and further research into the interplay between obesity, treatment efficacy, and patient survival in mCRC. However, further investigation is warranted to substantiate the findings of this study.

show abstract

Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO

Cited by 6 publications

References 17 publications

Predicción de resultados a corto plazo tras hemicolectomía derecha laparoscópica. ¿Es la sarcopenia superior a otros métodos?

Predicción de resultados a corto plazo tras hemicolectomía derecha laparoscópica. ¿Es la sarcopenia superior a otros métodos?

Deep learning‐based assessment of body composition and liver tumour burden for survival modelling in advanced colorectal cancer

Effect of body mass index on survival in patients with metastatic colorectal cancer receiving chemotherapy plus bevacizumab: a systematic review and meta-analysis

Contact Info

Product

Resources

About